explore -WSS

explore

author：knowledge 2025-08-11 08:01:00 - browse：12

Humana’s Medicare Advantage enrollees got care in the hospital and physician clinics way more often than the company predicted at the end of 2023, forcing the health insurance giant on Thursday to drastically slash its profit projections for both 2023 and 2024.

Those higher medical costs will wipe away more than $775 million of profit that Humana had expected to bank for 2023. Humana also is “currently assessing the expected impact of emerging utilization trends on its 2024 outlook, which is anticipated to be material if current trends continue,” according to the company’s update to investors.

Humana’s bad news for Wall Street didn’t end there: The company said it appears it only added just 100,000 new Medicare Advantage members from the most recent enrollment period that ended last month — down from estimates that it would enroll anywhere from 325,000 to 435,000 people.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Vir antibody drug aimed at influenza A fails in clinical trial

leisure time

WSS

Winning ticket for $1 billion Powerball jackpot sold in California

Why getting cancer drugs just got harder for rural patients

Flu vaccine offering decent levels of protection this winter, new data show

Driven by the pandemic, applicants flood public health schools

RaDonda Vaught to speak at CommonSpirit event on patient safety

FDA does about

entertainment

explore

leisure time

In age of alternative facts, a scholarly course on calling out crap

Hospitals struggle to profit from CAR

How to save PrEP access — and even expand it

7 more heat

Supreme Court strikes down use of affirmative action

Why getting cancer drugs just got harder for rural patients

How to save PrEP access — and even expand it

How to fix the rural physician shortage in the U.S.

Drug repurposing or repositioning? The language matters

Vir antibody drug aimed at influenza A fails in clinical trial

leisure time

Congress gives doctors Medicare pay bump

How to address the problem of discarded donor organs

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

FDA does about

FogPharma raises $145 million in rare Series E round

hotspot

explore

focus

hotspot